Higher risk of microvascular complications in smokers with type 1 diabetes despite intensive insulin therapy

Microvascular Research

Volumn 92, Issue , 2014, Pages 79-84

  Uruska, A ^a   Araszkiewicz, A ^a   Uruski, P ^a   Zozulinska Ziolkiewicz, D ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; HEMOGLOBIN A1C; SHORT ACTING INSULIN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; FEMALE; HUMAN; HUMAN CELL; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SMOKING; SYSTOLIC BLOOD PRESSURE; WAIST HIP RATIO; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; METABOLISM; POLAND;

ADULT; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MALE; POLAND; PROSPECTIVE STUDIES; RISK FACTORS; SMOKING;

EID: 84895918158     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2014.01.002     Document Type: Article

References (58)

1. Albers J.W., Herman W.H., et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 2010, 33(5):1090-1096.
2. Anon Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology 1991, 98(5 Suppl.):741-756.
3. Anon The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med. 1993, 329(14):977-986.
4. Anon Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven-year prospective study. The Microalbuminuria Collaborative Study Group. Diabet. Med. 1999, 16(11):918-925.
5. Anon KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am. J. Kidney Dis. 2007, 49(2 Suppl. 2):S12-S154.
6. Araszkiewicz A., Zozulinska D., et al. Is intensive functional insulin therapy the method of choice in newly diagnosed type-1 diabetes mellitus?. Pol. Merkur. Lekarski 2004, 17(101):463-466.
7. Araszkiewicz A., Zozulinska-Ziolkiewicz D., et al. Knowledge after five-day teaching program in intensive insulin therapy performed at the onset of type 1 diabetes influence the development of late diabetic complications. Diabetes Res. Clin. Pract. 2008, 81(1):61-67.
8. Bishop F.K., Maahs D.M., et al. Lifestyle risk factors for atherosclerosis in adults with type 1 diabetes. Diab. Vasc. Dis. Res. 2009, 6(4):269-275.
9. Borissova A.M., et al. The effect of smoking on peripheral insulin sensitivity and plasma endothelin level. Diabetes Metab. 2004, 30(2):147-152.
10. Bott U., Jorgens V., et al. Predictors of glycaemic control in type 1 diabetic patients after participation in an intensified treatment and teaching programme. Diabet. Med. 1994, 11(4):362-371.
11. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54(6):1615-1625.
12. Chaturvedi N., Stephenson J.M., et al. The relationship between smoking and microvascular complications in the EURODIAB IDDM Complications Study. Diabetes Care 1995, 18(6):785-792.
13. Esteves J.F., Kramer C.K., et al. Prevalence of diabetic retinopathy in patients with type 1 diabetes mellitus. Rev. Assoc. Med. Bras. 2009, 55(3):268-273.
14. Fagerudd J., Forsblom C., et al. Implementation of guidelines for the prevention of diabetic nephropathy. Diabetes Care 2004, 27(3):803-804.
15. Gerber P.A., Locher R., et al. Smoking is associated with impaired long-term glucose metabolism in patients with type 1 diabetes mellitus. Nutr. Metab. Cardiovasc. Dis. 2013, 23(2):102-108.
16. Hammes H.P., Kerner W., et al. Diabetic retinopathy in type 1 diabetes-a contemporary analysis of 8,784 patients. Diabetologia 2011, 54(8):1977-1984.
17. Hellerstein M.K., Benowitz N.L., et al. Effects of cigarette smoking and its cessation on lipid metabolism and energy expenditure in heavy smokers. J. Clin. Invest. 1994, 93(1):265-272.
18. Helve E., Yki-Jarvinen H., Koivisto V.A. Smoking and insulin sensitivity in type I diabetic patients. Metabolism 1986, 35(9):874-877.
19. Hofstetter A., et al. Increased 24-hour energy expenditure in cigarette smokers. N. Engl. J. Med. 1986, 314(2):79-82.
20. Hovind P., Tarnow L., et al. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 2003, 26(4):1258-1264.
21. Idzior-Walus B., Mattock M.B., et al. Factors associated with plasma lipids and lipoproteins in type 1 diabetes mellitus: the EURODIAB IDDM Complications Study. Diabet. Med. 2001, 18(10):786-796.
22. Jensen T., Borch-Johnsen K., et al. Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia 1987, 30(3):144-148.
23. Kilpatrick E.S., Rigby A.S., et al. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 2008, 31(11):2198-2202.
24. Kiowski W., et al. Diminished vascular response to inhibition of endothelium-derived nitric oxide and enhanced vasoconstriction to exogenously administered endothelin-1 in clinically healthy smokers. Circulation 1994, 90(1):27-34.
25. Klein R., Klein B.E., et al. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30years. Arch. Ophthalmol. 1984, 102(4):520-526.
26. Koide M., et al. Nicotine exposure, mimicked smoking, directly and indirectly enhanced protein kinase C activity in isolated canine basilar artery, resulting in enhancement of arterial contraction. J. Cereb. Blood Flow Metab. 2005, 25(3):292-301.
27. Koivisto V.A., Stevens L.K., et al. Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group. Diabetes Care 1996, 19(7):689-697.
28. Krolewski A.S., Warram J.H., et al. The changing natural history of nephropathy in type I diabetes. Am. J. Med. 1985, 78(5):785-794.
29. Krolewski A.S., Warram J.H., et al. Risk of proliferative diabetic retinopathy in juvenile-onset type I diabetes: a 40-yr follow-up study. Diabetes Care 1986, 9(5):443-452.
30. Lovestam-Adrian M., Agardh C.D., et al. Diabetic retinopathy, visual acuity, and medical risk indicators: a continuous 10-year follow-up study in Type 1 diabetic patients under routine care. J. Diabetes Complications 2001, 15(6):287-294.
31. Mattock M.B., Cronin N., et al. Plasma lipids and urinary albumin excretion rate in Type 1 diabetes mellitus: the EURODIAB IDDM Complications Study. Diabet. Med. 2001, 18(1):59-67.
32. Molitch M.E., Steffes M., et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 2010, 33(7):1536-1543.
33. Moy C.S., LaPorte R.E., et al. Insulin-dependent diabetes mellitus mortality. The risk of cigarette smoking. Circulation 1990, 82(1):37-43.
34. Muhlhauser I. Cigarette smoking and diabetes: an update. Diabet. Med. 1994, 11(4):336-343.
35. Muller U.A., Femerling M., et al. Intensified treatment and education of type 1 diabetes as clinical routine. A nationwide quality-circle experience in Germany. ASD (the Working Group on Structured Diabetes Therapy of the German Diabetes Association). Diabetes Care 1999, 22(Suppl. 2):B29-B34.
36. Naskret D., Zozulinska-Ziolkiewicz D.A., et al. Albuminuria and VEGF as early markers of cardiovascular disturbances in young type 1 diabetic patients. Microvasc. Res. 2010, 80(3):440-444.
37. Perneger T.V., Brancati F.L., et al. End-stage renal disease attributable to diabetes mellitus. Ann. Intern. Med. 1994, 121(12):912-918.
38. Polak J.F., Backlund J.Y., et al. Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes 2011, 60(2):607-613.
39. Rossing P., Hougaard P., et al. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care 2002, 25(5):859-864.
40. Roy M.S., Klein R., et al. The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the United States. Arch. Ophthalmol. 2004, 122(4):546-551.
41. Sawicki P.T., Didjurgeit U., et al. Smoking is associated with progression of diabetic nephropathy. Diabetes Care 1994, 17(2):126-131.
42. Scemama O., Hamo-Tchatchouang E., et al. Difficulties of smoking cessation in diabetic inpatients benefiting from a systematic consultation to help them to give up smoking. Diabetes Metab. 2006, 32(5 Pt 1):435-441.
43. Scott L.J., Warram J.H., et al. A nonlinear effect of hyperglycemia and current cigarette smoking are major determinants of the onset of microalbuminuria in type 1 diabetes. Diabetes 2001, 50(12):2842-2849.
44. Sinha R.N., Patrick A.W., et al. A six-year follow-up study of smoking habits and microvascular complications in young adults with type 1 diabetes. Postgrad. Med. J. 1997, 73(859):293-294.
45. Stratton I.M., Kohner E.M., et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001, 44(2):156-163.
46. Suzuki A., Funasaka T., Matsumoto H. The contractive mechanism of nicotine in isolated aorta of rabbits, with special reference to catecholamine release. Kobe J. Med. Sci. 1973, 19(3):111-125.
47. Targher G., Alberiche M., et al. Cigarette smoking and insulin resistance in patients with noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 1997, 82(11):3619-3624.
48. Tesfaye S., Chaturvedi N., et al. Vascular risk factors and diabetic neuropathy. N. Engl. J. Med. 2005, 352(4):341-350.
49. Toda N., Toda H. Nitric oxide-mediated blood flow regulation as affected by smoking and nicotine. Eur. J. Pharmacol. 2010, 649(1-3):1-13.
50. Tseng L.N., Tseng Y.H., et al. Prevalence of hypertension and dyslipidemia and their associations with micro- and macrovascular diseases in patients with diabetes in Taiwan: an analysis of nationwide data for 2000-2009. J. Formos. Med. Assoc. 2012, 111(11):625-636.
51. Uruska A., Araszkiewicz A., et al. Insulin resistance is associated with microangiopathy in type 1 diabetic patients treated with intensive insulin therapy from the onset of disease. Exp. Clin. Endocrinol. Diabetes 2010, 118(8):478-484.
52. Vergouwe Y., Soedamah-Muthu S.S., et al. Progression to microalbuminuria in type 1 diabetes: development and validation of a prediction rule. Diabetologia 2010, 53(2):254-262.
53. Vinik A.I., Park T.S., et al. Diabetic neuropathies. Diabetologia 2000, 43(8):957-973.
54. Voulgari C., Psallas M., et al. The association between cardiac autonomic neuropathy with metabolic and other factors in subjects with type 1 and type 2 diabetes. J. Diabetes Complications 2011, 25(3):159-167.
55. Waden J., Forsblom C., et al. A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes 2009, 58(11):2649-2655.
56. Wegner M., Piorunska-Stolzmann M., et al. Does oxidized LDL contribute to atherosclerotic plaque formation and microvascular complications in patients with type 1 diabetes?. Clin. Biochem. 2012, 45(18):1620-1623.
57. White N.H., Sun W., et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes 2010, 59(5):1244-1253.
58. Wierusz-Wysocka B., Zozulinska D.A., et al. Higher levels of HDL cholesterol are associated with a decreased likelihood of albuminuria in patients with long-standing type 1 diabetes: response to Molitch et al. Diabetes Care 2006, 29(5):1176-1177.